Will natural products remain an important source of drug research for the future?

被引:47
作者
Nisbet, LJ [1 ]
Moore, M [1 ]
机构
[1] XENOVA DISCOVERY LTD, SLOUGH SL1 4EF, BERKS, ENGLAND
关键词
D O I
10.1016/S0958-1669(97)80124-3
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
In the highly competitive environment of contemporary pharmaceutical research, natural products provide a unique element of molecular diversity and biological functionality which is indispensable for drug discovery. The emergence of strategies to deliver drug leads from natural products within the same time frame as synthetic chemical screening has eliminated a major limitation of the past. At a more functional level, the application of molecular genetics techniques has permitted the manipulation of biosynthetic pathways for the generation of novel chemical species as well as rendering hitherto uncultivatable microorganisms accessible for secondary metabolite generation. These developments augur well for an industry confronted with the challenge of finding lead compounds directed at the plethora of new targets arising from genomics projects. The exploitation of structural chemical databases comprising a wide variety of chemotypes, in conjunction with databases on target genes and proteins, will facilitate the creation of new chemical entities through computational molecular modelling for pharmacological evaluation. (C) Current Biology Ltd ISSN 0958-1669.
引用
收藏
页码:708 / 712
页数:5
相关论文
共 32 条
[1]  
BOLLAG DM, 1995, CANCER RES, V55, P2325
[2]   Inhibition of plasminogen activator inhibitor-1 activity by two diketopiperazines, XR330 and XR334 produced by Streptomyces sp. [J].
Bryans, J ;
Charlton, P ;
ChicarelliRobinson, I ;
Collins, M ;
Faint, R ;
Latham, C ;
Shaw, I ;
Trew, S .
JOURNAL OF ANTIBIOTICS, 1996, 49 (10) :1014-1021
[3]   XR5118, a novel modulator of plasminogen activator inhibitor-1 (PAI-1), increases endogenous tPA activity in the rat [J].
Charlton, P ;
Faint, R ;
Barnes, C ;
Bent, F ;
Folkes, A ;
Templeton, D ;
Mackie, I ;
Machin, S ;
Bevan, P .
FIBRINOLYSIS & PROTEOLYSIS, 1997, 11 (01) :51-56
[4]  
Charlton PA, 1996, THROMB HAEMOSTASIS, V75, P808
[5]   To market, to market - 1995 [J].
Cheng, XM .
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 31, 1996, 31 :337-355
[6]  
CHENG XM, 1994, ANNU REP MED CHEM, V29, P331
[7]  
CHICARELLIROBIN.MI, 1997, 3 IBC INT C NAT PROD
[9]  
CRAGG GM, 1997, PHYTOCHEMICAL DIVERS, P1
[10]  
DALE IL, 1996, ANN ONCOL S1, V7, P123